We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Btg Plc | LSE:BTG | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 840.00 | 839.00 | 840.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
01/11/2016 09:07 | Latest information from Oct 28,third qtr Sanofi resultsIn the third quarter, sales of Lemtrada® increased 69.1% to 112 million, including 64 million in the U.S. (up 66.7%) and 37 million in Europe (up 81.8%), mainly generated in the UK. Year-to-date sales of Lemtrada® were up 95.1% to 308 million.That's good news but maybe the trolls have found something less encouraging.The whole sector has been under pressure from the ridiculously dysfunctional US election that makes you question the very concept of democracy. | steeplejack | |
01/11/2016 08:32 | Is that a cyber attack or a disaster looming! | fhmktg | |
31/10/2016 17:42 | Fhmktg Hope we make it , it is a lonely board following BTG . Strange why so little people follow this. | bargainbob | |
31/10/2016 11:47 | Lemtrada with us until December 2017 so some very useful cash flow until then.November 15th for update numbers. Currency will have helped again. Varithena will probably disappoint again, but submission of PneumRx to FDA should come in next two months.The outcome of TrumpvClinton is weighing on sentiment for the US healthcare sector and general pessimism for the world markets.BTG has a terrific story to tell with over 20% compound growth in revenue and excellent margins.I just hope I'm still here to see the share price double over the next few years! | fhmktg | |
28/10/2016 16:24 | posted by Dave Gasser Just been taking a look a sanofi third quarter sales of Lemtrada® they have increased by 69.1% to €112 million, including €64 million in the U.S. (up 66.7%) and €37 million in Europe (up 81.8%), mainly generated in the UK. Year-to-date sales of Lemtrada® were up 95.1% to €308 million. that should help the bottom line. It's a pity BTG stoped issuing quarterly results as they are so handy . hxxp://mediaroom.san BE HAPPY Dave | bargainbob | |
28/10/2016 16:20 | Crying out for a pay back here . No , share growth or divi. | bargainbob | |
28/10/2016 13:31 | Painful it is as well! | fhmktg | |
28/10/2016 12:39 | FTSE 100 up and BTG loosing ground again on no news and no volume 2 RECOMMENDATIONS UPGRADES LAST WEEK RAISING TARGET PRICES to 860-900p by Deutsche and Numis , but market wants BTG down - this is reality .... | a1ord53 | |
20/10/2016 17:37 | BTG plc (BTG) Upgraded to “Buy” at Numis Securities Ltd Posted by Trent Williams on Oct 17th, 2016 // No Comments BTG plc logoBTG plc (LON:BTG) was upgraded by equities researchers at Numis Securities Ltd to a “buy” rating in a research note issued on Monday. The firm currently has a GBX 900 ($11.14) price target on the stock. Numis Securities Ltd’s target price points to a potential upside of 29.87% from the stock’s previous close. | a1ord53 | |
19/10/2016 08:40 | biotec flying in USA yesterday .Surprised no pull through here today. | bargainbob | |
14/10/2016 09:05 | Oh thanks I see it now . | bargainbob | |
14/10/2016 08:31 | It's on the news section for today.A software certification for aiding Therasphere. | fhmktg | |
14/10/2016 08:28 | Is it on the BTG website. | bargainbob | |
14/10/2016 07:34 | Another brick in the competency wall today. Credibility with the academic community grows.Now that's how to grow a business!Well done the Therasphere team. | fhmktg | |
07/10/2016 18:58 | Share of the week [...] | bargainbob | |
07/10/2016 09:57 | The henny-penny theory of investment does not seem to be working here. It never makes sense with a solid company like BTG to rush about the street shouting "The sky is falling" when the share price drops. Much better to take the opportunity to buy. CT's (and others') gloomy prognostications seem to have been completely wrong again. | muffmitz | |
07/10/2016 08:10 | A balanced piece in the Telegraph today rather unfortunately headed "Inside KTG!"listing pros and cons | steeplejack | |
07/10/2016 07:22 | Does the cash from the settlement for the claim against Biocompatibles come from BTG or from the previous owners and their insurers ? | fhmktg | |
07/10/2016 06:35 | Oh dear - Tempus is having a bad day! Having previously been a fan of BTG, 'Tempus' (The Times) now says "On 36 times earnings, I would wait for a further period of price weakness to buy" and concludes "Avoid - long term picture is good but multiple looks high". This seams a bit contrarian given that I am sure Tempus has recommended to buy BTG at higher multiples/higher share price before, perhaps he has been influenced by CT! To to fair, I think Tempus is having a bad day because he also recommends buying BAE (despite its insane pension deficit) and buying DFS (despite the fact that they just sell ... er ... Sofas!). I think he should go and lie down in a darkened room for a bit. | spyder | |
06/10/2016 21:10 | The broker reports will follow shortly , will the £7 hold Captain. | bargainbob | |
06/10/2016 19:59 | I agree gregmorg. Other good quotes from the article that CT kindly referred to us (thanks CT) include - "the good news is that this product works extraordinarily well. There is not a patient that we're aware of who hasn't responded well" & 'Day by day, BTG sees more physicians using Varithena'. It has been very very slow, but perhaps there are some nascent signs of the success of Varithens. | spyder | |
06/10/2016 15:43 | £3 by Xmas, then? LOL | harijan | |
06/10/2016 15:17 | Good news ref lc bead. Still not convinced ref varithena. | cockneytrader |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions